Raymond James Financial Inc. Acquires Shares of 201,623 Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Raymond James Financial Inc. purchased a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 201,623 shares of the biopharmaceutical company's stock, valued at approximately $1,722,000. Raymond James Financial Inc. owned about 0.13% of Ocular Therapeutix at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the company. Atlas Capital Advisors Inc. purchased a new position in Ocular Therapeutix in the 4th quarter valued at approximately $43,000. AlphaQuest LLC acquired a new position in shares of Ocular Therapeutix in the fourth quarter valued at approximately $53,000. Palumbo Wealth Management LLC purchased a new position in shares of Ocular Therapeutix during the fourth quarter valued at approximately $100,000. Cibc World Markets Corp acquired a new stake in Ocular Therapeutix during the fourth quarter worth approximately $124,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in Ocular Therapeutix in the 4th quarter worth approximately $149,000. Hedge funds and other institutional investors own 59.21% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on OCUL. William Blair started coverage on Ocular Therapeutix in a research note on Tuesday, April 8th. They set an "outperform" rating on the stock. Needham & Company LLC lowered their price target on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating for the company in a report on Tuesday. HC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. Royal Bank of Canada assumed coverage on shares of Ocular Therapeutix in a report on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 target price for the company. Finally, JMP Securities set a $19.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $16.25.

Insider Transactions at Ocular Therapeutix

In related news, insider Pravin Dugel sold 21,475 shares of the business's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $6.87, for a total transaction of $147,533.25. Following the transaction, the insider now directly owns 3,520,318 shares of the company's stock, valued at approximately $24,184,584.66. The trade was a 0.61 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 3.50% of the company's stock.

Ocular Therapeutix Trading Down 1.8 %

OCUL traded down $0.13 during trading on Wednesday, hitting $7.05. 1,985,608 shares of the company's stock were exchanged, compared to its average volume of 1,428,752. Ocular Therapeutix, Inc. has a 1 year low of $4.79 and a 1 year high of $11.78. The stock has a 50 day moving average price of $7.42 and a 200 day moving average price of $8.35. The firm has a market cap of $1.12 billion, a P/E ratio of -5.34 and a beta of 1.51. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. The business had revenue of $17.08 million for the quarter, compared to analysts' expectations of $16.89 million. As a group, analysts expect that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.